A new study published in the International Journal of General Medicine showed that physicians may reliably estimate the ...
O’Sullivan is an interventional radiologist — a physician who specializes in minimally invasive, targeted treatments. In mid-March at the Society of Interventional Radiology scientific meeting in ...
August 4, 2010 (Leverkusen, Germany) — The use of rivaroxaban (Xarelto, Bayer/Johnson & Johnson) is noninferior to standard medical therapy for reducing the cumulative incidence of symptomatic ...
Giving the direct oral anticoagulant (DOAC) edoxaban for 12 months rather than 3 months is better for preventing thrombotic events in patients with active cancer and isolated deep-vein thrombosis (DVT ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window AMSTERDAM -- A ...
Please provide your email address to receive an email when new articles are posted on . Longer vs. shorter-duration anticoagulation reduces thrombotic event risk for patients with cancer and isolated ...
Boehringer Ingelheim has enrolled the first patient in a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE).
When most of us think of a serious medical emergency, we usually think of sudden events such as heart attacks, strokes or serious injuries from a car crash. But some threats develop quietly, with ...
Large COVID vaccination study found that thrombosis and thrombocytopenia are very rare complications
In a recent Nature Communications journal paper, researchers determine the rates of thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia following severe acute respiratory syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback